Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib and Chemoradiation as Adjuvant Treatment for Resected Pancreatic Cancer
NCT01013649Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2010
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of erlotinib in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Survival [Phase II] up to 6.2 years and Overall Survival [Phase III] up to 12.8 years. Started Apr 2010; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01013649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013649.